{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T03:43:02Z","timestamp":1649130182723},"reference-count":0,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JADPRO"],"published-print":{"date-parts":[[2020,7,1]]},"DOI":"10.6004\/jadpro.2020.11.5.8","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T14:43:08Z","timestamp":1595515388000},"source":"Crossref","is-referenced-by-count":0,"title":["Polatuzumab Vedotin for the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients"],"prefix":"10.6004","volume":"11","author":[{"given":"Melanie","family":"Douglas, MS, PA-C","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","published-online":{"date-parts":[[2020,7,1]]},"container-title":["Journal of the Advanced Practitioner in Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T14:43:27Z","timestamp":1595515407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.advancedpractitioner.com\/issues\/volume-11,-number-5-(july-2020)\/polatuzumab-vedotin-for-the-treatment-of-relapsedrefractory-diffuse-large-b-cell-lymphoma-in-transplant-ineligible-patients.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,7,1]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.6004\/jadpro.2020.11.5.8","relation":{},"ISSN":["2150-0878"],"issn-type":[{"value":"2150-0878","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}